CHEMOTHERAPY FOR METASTATIC NON-SMALL CELL BRONCHOGENIC-CARCINOMA - EST 2575, GENERATION-III, HAM VERSUS CAMP
- 1 January 1981
- journal article
- research article
- Vol. 65 (11-1) , 959-963
Abstract
Between Sept. 1978 and March 1979 the Eastern Cooperative Oncology Group [USA] compared the CAMP (cyclophosphamide, doxorubicin, methotrexate, procarbazine) and HAM (hexamethylmelamine, doxorubicin, methotrexate) regimens in 154 patients with metastatic non-small cell bronchogenic carcinoma. Most patients were ambulatory (77%) and had not received prior radiotherapy (59%). HAM produced 2 complete responses (CR) and 8 partial responses (PR) (n = 77; 2.5% CR, 10.4% PR, 13% overall response); CAMP resulted in 5 CR and 12 PR (n = 77; 6.5% CR, 15.6% PR, 22% overall response). This difference was not statistically significant (P = 0.14 with Fisher''s exact 2-sided test), nor was the difference in overall median survival (HAM, 22.1 wk and CAMP, 19.3 wk). Responders had a significantly improved median survival (32.5 wk) compared to nonresponders (17.9 wk, P = 0.018). Ambulatory performance status and lack of prior radiotherapy were positive predictors for prolonged survival.This publication has 3 references indexed in Scilit:
- CHEMOTHERAPY FOR INOPERABLE, NON-SMALL CELL BRONCHOGENIC-CARCINOMA - EST 2575, GENERATION-II1981
- RESULTS OF A PHASE-II PROTOCOL FOR EVALUATION OF NEW CHEMOTHERAPEUTIC REGIMENS IN PATIENTS WITH INOPERABLE NON-SMALL CELL LUNG-CARCINOMA (EST-2575, GENERATION-I)1981
- Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP)JAMA, 1978